Q3 FY2026 · ended Sep 30, 2026 · Revenue $78.75M, -31.8% YoY · Filed Oct 30, 2026
Ligand Pharmaceuticals Incorporated (LGND) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $78.7 million and a net loss of $28.5 million. Free cash flow was -$27.7 million. As of Sep 30, 2026 it held $447.4 million in cash and investments and $1.2 billion in total debt.
Revenue
$78.75M
-31.8% vs year-ago quarter
Net income
$-28.48M
-124.3% vs year-ago quarter
Operating cash flow
$-27.59M
-310.8% vs year-ago quarter
Free cash flow
$-27.73M
-312.1% vs year-ago quarter
EPS
$-1.43
-125.2% vs year-ago quarter
Dividend per share
None
Shares outstanding
20.00M
+1.6% vs year-ago quarter
Net cash
$-706.81M
Q3 FY2026
Operating margin
10.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGND (Nasdaq), LGNDZ (OTC), LGNXZ (OTC), LGNYZ (OTC), LGNZZ (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 886163
- Former names
- LIGAND PHARMACEUTICALS (until Sep 13, 1994)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $78.7M | $63.7M | $51.7M | $59.7M | $115.5M |
| Operating income | -$15.8M | $8.6M | $17.4M | $15.3M | $55.4M |
| Net income | -$28.5M | $48.5M | -$13.3M | $44.8M | $117.3M |
| Diluted EPS | -$1.43 | $2.22 | -$0.67 | $2.17 | $5.68 |
| Operating cash flow | -$27.6M | $24.0M | $48.7M | $45.9M | $13.1M |
| Free cash flow | -$27.7M | $24.0M | $48.5M | $45.9M | $13.1M |
| Total assets | $2.2B | $2.2B | $1.5B | $1.6B | $1.5B |
| Total liabilities | $1.3B | $1.2B | $534.8M | $543.4M | $526.6M |
| Stockholders' equity | $961.8M | $967.5M | $997.3M | $1.0B | $950.2M |
| Cash and investments | $447.4M | $1.4B | $779.4M | $733.5M | $664.5M |
| Total debt | $1.2B | $1.1B | $5.1M | $5.4M | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 22, 2026 | Sep 22, 2026 |
| 8-K/A | Amended current report | Sep 2, 2026 | Jul 14, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
All 1000 Ligand Pharmaceuticals Incorporated SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.